StreetAlpha.app
Home › Stocks › ALDX

Aldeyra Therapeutics, Inc. (ALDX)

$0.84
▲ +16.39%
LAST CLOSE · NOV 20

Aldeyra Therapeutics is a Concord, Massachusetts biotech developing drug candidates for eye and other immune system diseases. It last closed at $0.84 on Nov 20, up 16.39% on the day. For the quarter ended Sep 2026, ALDX reported EPS of -$0.06. Over its last 8 reports the stock moved an average of 8.2% the session after earnings. Over the last 12 months ALDX insiders bought $664K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ALDX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ALDX.

Key Stats

Last 12 months
Results
Net income
−$19.1M
EPS (diluted)
−$0.31
Valuation
Market cap
$50.7M
60.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.0M
At Sep 30
Shareholder equity
$35.2M
Shares outstanding
60.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$57.8M−$57.8MFY2021FY2022: −$62.0M−$62.0MFY2022FY2023: −$37.5M−$37.5MFY2023FY2024: −$55.9M−$55.9MFY2024FY2025: −$33.8M−$33.8MFY2025

From ALDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
May 4
2023 · next date not set yet
Reported EPS
-$0.06
Quarter ended Sep 2026
Year ago EPS
-$0.13
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.27Dec '24Mar 2025: -$0.17Mar '25Jun 2025: -$0.16Jun '25Sep 2025: -$0.13Sep '25Dec 2025: -$0.10Dec '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.09Jun '26Sep 2026: -$0.06Sep '26Latest -$0.06
Revenue by quarter
Not enough quarters on file yet.
How ALDX moved after its last 8 reports
Average move the session after a report ±8.2%
May 4, 2023Time not announced+2.1%
Mar 9, 2023Time not announced+7.2%
Nov 10, 2022Time not announced+6.2%
Aug 5, 2022Time not announced+10.9%
May 5, 2022Time not announced−5.1%
Mar 17, 2022Time not announced+16.3%
Oct 28, 2021Time not announced+9.2%
Aug 5, 2021Time not announced+8.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ALDXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ALDX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ALDX

Technical Analysis

ALDX · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend, nearing overbought

The stock sits between its 20 and 50 day averages. It is 131% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 60), near overbought. The nearest support is the Pivot at $0.79, and the nearest resistance the 50 day average at $0.90.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNear overbought
VolatilityHigh, 10.8%/day
Key levels
$5.9352 week high+606.0%
$1.94200 day average+131.0%
$1.40Swing high (Sep 23)+66.7%
$1.27100 day average+51.2%
$0.93Pivot R1+10.7%
$0.9050 day average+7.1%
$0.84Last close
$0.79Pivot−6.0%
$0.70Pivot S1−16.7%
$0.6520 day average−22.6%
$0.65Swing low (Oct 16)−22.6%
$0.5352 week low−36.9%
Indicators
RSI (14)60.42Strong, overbought above 70Neutral
MACD-0.04Above its signal lineBullish
Stochastic84.6Near the top of its rangeOverbought
ADX (14)26.6Trending up
Williams %R-13.5Oversold below −80, overbought above −20Overbought
CCI (20)297.8Oversold below −100, overbought above 100Overbought
Rate of change+32.5%Change over 10 sessionsBullish
ATR (14)$0.09Typical daily range, 10.8% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALDX

What happened before

See how ALDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ALDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ALDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ALDXHow many large options trades hit ALDX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ALDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼35 buying vs 70 selling
  • ▼Held by funds -9.5 pts
  • ▼Funds holding -11
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding97108−10.2%
In funds' top 1001−100.0%
Held by funds51.4%60.9%−9.5 pts
New / increased13 / 2218 / 31−28.6%
Reduced / sold out45 / 2543 / 37−12.5%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ALDX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$664K6 buys · 4 insiders
Sold$00 sales · 0 insiders
Cluster buy: 3 insiders bought $140K between Nov 11 and Nov 12.
2026-03 bought $105K2026-06 bought $418K2026-11 bought $140KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 12Darlene M Deptula-hicksDirectorBuy7,500$0.65$5K
Nov 11Richard DouglasDirectorBuy200,000$0.64$129K
Nov 11Michael AlfieriPrincipal Financial OfficerBuy10,000$0.65$7K
Jun 3Todd C BradyPresident and CEOBuy250,000$1.67$418K
Mar 19Richard DouglasDirectorBuy70,000$1.40$98K
Mar 18Michael AlfieriPrincipal Financial OfficerBuy5,000$1.42$7K
Every insider buy and sale for ALDX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ALDX insider trades →

From SEC Form 4 filings by ALDX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALDX is in one of them and how their past ALDX trades turned out.

ALDX in the AI portfolios
Loading…

ALDX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALDX in an article yet. Here's the latest on the wider market.

ALDX in the news

About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company based in Concord, Massachusetts, that develops drug candidates for diseases of the immune system. Its approach uses a family of small molecules called RASP modulators, which act on many proteins at once rather than a single target. Its most advanced candidate, reproxalap, is being studied for dry eye disease and allergic conjunctivitis, and the company is also developing treatments for retinal conditions. It has no approved products yet and plans to sell any future drugs directly or through partners.

Headquarters
Concord, MA